BioNTech Says 'no Evidence' Its Jabs Need Adapting For Variants
Sumaira FH 1 month ago Mon 10th May 2021 | 10:06 PM
German firm BioNTech said Monday that the Covid-19 vaccine it developed with Pfizer does not require any modifications to work against variants of the virus, as it announced new plans to ramp up production of the jabs
Berlin, (APP - UrduPoint / Pakistan Point News - 10th May, 2021 ) :German firm BioNTech said Monday that the Covid-19 vaccine it developed with Pfizer does not require any modifications to work against variants of the virus, as it announced new plans to ramp up production of the jabs.
"The aim of this study is to explore the regulatory pathway that BioNTech and Pfizer would pursue if SARS-CoV-2 were to change enough to require an updated vaccine," it said.
An assessment is also ongoing on whether a possible third dose could prolong immunity and protect against variants.
The jab developed by BioNTech/Pfizer was the first to win authorisation in the West, and has since been deployed in dozens of countries worldwide.
- 'More than enough vaccines' - BioNTech said in a separate statement Monday that it was setting up a production facility in Singapore -- its first outside Europe -- to produce hundreds of millions of mRNA-vaccines a year.
In a bid to rapidly raise global production capacities to cope with huge global demand for their Covid vaccine, BioNTech and Pfizer have set out licensing and manufacturing partnerships with other pharmaceutical companies such as Merck, Novartis and Sanofi.
Both BioNTech and Pfizer have argued that the extension of such cooperation is what would help ensure a wider supply of vaccines, and not a patent waiver as the United States has sought.
Reiterating the argument, Sahin told journalists Monday that BioNTech believes that "together with other vaccines developers, in the next 9 to 12 months there will be more than enough vaccines produced".
"There is absolutely no need for waiving patents," he said.